PT  - JOURNAL ARTICLE
AU  - Sinclair, Heather Q.
ED  - Ezekowitz, Michael D.
TI  - The Safety and Tolerability of Betrixaban Therapy
DP  - 2010 May 01
TA  - MD Conference Express
PG  - 14--15
VI  - 10
IP  - 2
4099  - http://mdc.sagepub.com/content/10/2/14.2.short
4100  - http://mdc.sagepub.com/content/10/2/14.2.full
AB  - The oral direct factor Xa inhibitor betrixaban, at doses of 40 mg, 60 mg, and 80 mg once daily, is safe and well tolerated compared with dose-adjusted warfarin in patients with nonvalvular atrial fibrillation (AF) or atrial flutter. This article presents results from the Phase II, randomized, multicenter EXPLORE-Xa Trial [NCT00742859].